蘑菇视频APP

CAMBRIDGE, Mass., October 28, 2020 鈥� 蘑菇视频APP today announced the unveiling of Senda Biosciences, a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans and coevolved nonhuman species. Senda is pioneering a new research discipline it calls intersystems biology, and it will create novel treatments for human disease. Senda combines multiple research efforts in intersystems biology originated by Flagship Labs across several predecessor companies, and has been capitalized with $88 million to date.

Intersystems biology focuses on how molecular connections between botanical, bacterial, and human cells鈥攃oevolved over millennia鈥攄efine health and disease. It builds on a decade of advances in research on the microbiome, 鈥渙mics,鈥� and big data, and moves beyond traditional taxonomic descriptions to delineate interspecies interactions using new techniques in machine learning and computational biology. Senda鈥檚 discovery platform has generated unique, actionable insights into the trillions of interspecies molecular connections in the human body, and it harnesses the power of this 鈥減harmacy within us鈥� with novel pharmacological approaches. The platform will enable the creation of entirely new categories of medicines, with applications in a wide variety of therapeutic areas.

Medicines exploiting insights from intersystems biology will:

• Achieve systemic health effects while minimizing drug exposure, by targeting the nonhuman species in our body鈥檚 ecosystem;
• Deliver compounds in highly precise ways, via selectively activated molecules;
• Deploy large biomolecules鈥攕uch as peptides and nucleic acids鈥攖hrough oral administration for the first time.

鈥淔or more than a decade, Flagship has been at the forefront of discoveries and therapeutic development focused on the microbiome. Intersystems biology represents the next frontier in our understanding of human biology,鈥� says Noubar Afeyan, PhD, founder and CEO of 蘑菇视频APP. 鈥淏ased on its unprecedented view into how species like plants and bacteria interact with human cells at the molecular level, and Senda鈥檚 ability to disrupt and direct how these interactions occur, the company is uniquely positioned to develop transformative therapeutic modalities in multiple disease categories. By introducing altogether new types of medicines鈥攑otentially safer, more precise, and more convenient than current standards of care鈥擲enda can and will change patients鈥� lives.鈥�

The Senda discovery platform provides never-before-seen molecular resolution into interspecies connections, with interactions mapped to exact locations across the human gastrointestinal tract. As a result, the platform can identify, quantify, and locate molecular connections with hundreds of times the diversity of traditional stool-based sampling methods commonly used today. The power of the Senda platform is illustrated by six ongoing preclinical programs with an IND submission expected for each by the end of 2022 (all of them precision small-molecule drugs):

• Neurology: multiple sclerosis and Parkinson鈥檚 disease
• Oncology: immuno-oncology and colorectal cancer
• Chronic and metabolic disease: chronic kidney disease and obesity

Senda is also developing novel plant- and bacteria-derived transfer modalities for large biomolecules, inspired by the natural evolutionary molecular communication features of these nonhuman species.

Senda is the result of multiple research efforts by Flagship Labs, 蘑菇视频APP鈥檚 innovation foundry, and was co-founded by Partners David Berry, MD, PhD, and Ignacio Martinez, MBA; Principal John Casey, PhD; Senior Associates David Kolesky, PhD, and Hok Hei Tam PhD; and Associate Ellen van Rooijen, PhD.

Senda鈥檚 senior leadership team includes Chief Executive Officer Guillaume Pfefer, PhD, a 25-year veteran of the biotech and pharmaceutical industries who also serves as a CEO-Partner at 蘑菇视频APP. Guillaume Pfefer most recently served as Senior Vice President, Global Vaccine Leader for SHINGRIX, GlaxoSmithKline鈥檚 (GSK) vaccine for the prevention of shingles. Chief Scientific Officer Scott Plevy, MD, is a gastroenterologist and molecular immunologist who has previously held leadership positions at Synlogic and Janssen Immunology Research & Development.

Senda鈥檚 Board of Directors includes a number of accomplished entrepreneurs and industry thought leaders including Chairman John Mendlein, JD, PhD, Executive Partner at Flagship; Ignacio Martinez, MBA, General Partner at Flagship; David Berry, MD, PhD, General Partner at Flagship; Luis Cantarell, former President and CEO of Nestl茅 Health Science; Mary Szela, MBA, President and CEO of TriSalus Life Sciences; Luke O鈥橬eill, PhD, chair of Biochemistry at Trinity College Dublin; and Guillaume Pfefer, PhD, CEO of Senda Biosciences.

Guillaume Pfefer says, 鈥淚 have been fortunate to be part of the advancement of many groundbreaking medicines during my career, but it is a rare opportunity to be part of a company pioneering an entirely novel approach to treating some of society鈥檚 most intractable diseases. With the talents already assembled at team, directorship, and scientific advisory levels, we are uniquely equipped to rapidly position the company as the uncontested leader in the field of intersystems biology and make a difference in the lives of the countless patients who can benefit from Senda鈥檚 novel medicines.鈥�

About Senda Biosciences
Senda Biosciences is pioneering the field of intersystems biology to create novel treatments for human disease. Intersystems biology focuses on how molecular connections between botanical, bacterial, and human cells鈥攃oevolved over millennia鈥攄efine health and disease. Senda鈥檚 intersystems biology discovery platform, built using new techniques in machine learning and computational biology, has been able to generate novel, actionable insights into the trillions of interspecies molecular connections in the human body, and harnesses the power of this 鈥減harmacy within us鈥� with novel pharmacological approaches. The power of the Senda platform is illustrated by six preclinical programs in oncology, neurology, chronic disease, and metabolic disease. Senda was founded by Flagship Labs, the innovation foundry of 蘑菇视频APP. To learn more, please visit the company鈥檚 website at .

About 蘑菇视频APP
蘑菇视频APP conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has applied a unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $34 billion in aggregate value. To date, Flagship is backed by more than $4.4 billion of aggregate capital commitments, of which over $1.9 billion has been deployed toward the founding and growth of its pioneering companies alongside more than $10 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ: ), Denali Therapeutics (NASDAQ: ), Evelo Biosciences (NASDAQ: ), Foghorn Therapeutics (NASDAQ: ), Indigo Ag, Kaleido Biosciences (NASDAQ: ), Moderna (NASDAQ: ), Rubius Therapeutics (NASDAQ: ), Sana Biotechnology, Seres Therapeutics (NASDAQ: ), Sigilon Therapeutics, and Syros Pharmaceuticals (NASDAQ: ).